Q1 FY27 saw revenue up 25% and EBITDA up 36% year-on-year, driven by strong growth in specialty chemicals, nutrition, and chemical intermediates. Management expects sequential improvement, maintains full-year EBITDA guidance, and highlights robust CDMO pipeline and operational resilience.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.